Beam TherapeuticsのSMA 200
Beam TherapeuticsのSMA 200は何ですか。
Beam Therapeutics Inc.のSMA 200は$28 -14.20%です。
SMA 200の定義は何ですか。
SMA 200は、過去200日間の終値の非加重平均として計算された過去200日間の平均株価です。
Simple moving average of 200 days for a stock is an unweighted moving average over the past 200 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
NASDAQのセクタHealth CareにおけるSMA 200の企業と比べるBeam Therapeutics
Beam Therapeuticsは何をしますか。
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Beam Therapeuticsと類似のsma 200
- Reaves Utility Income FundのSMA 200は$27 +10.08%です。
- NikolaのSMA 200は$28 +0.00%です。
- PCS TechnologyのSMA 200は₨28 +5.04%です。
- TMXのSMA 200は$28 +13.52%です。
- BrickworksのSMA 200はAUD$28 -7.63%です。
- Surgery Partners IncのSMA 200は$28 +9.54%です。
- Beam TherapeuticsのSMA 200は$28 -14.20%です。
- Shanghai Kindly Med Instr CoのSMA 200は$28 +0.55%です。
- Shanghai Kindly Medical Instruments CoのSMA 200はHKD$28 +0.71%です。
- Hisense Kelon ElectricalのSMA 200はHKD$28 -34.43%です。
- DigicontentのSMA 200は₨28 +27.45%です。
- BlackRock Institutional Trust N.AのSMA 200は$28 +11.56%です。
- Reliance PowerのSMA 200は₨28 +6.66%です。